铂类和西妥昔单抗在无法进行根治性治疗的皮肤鳞状细胞癌中的活性。
Activity of platinum and cetuximab in cutaneous squamous cell cancer not amenable to curative treatment.
作者信息
Galbiati Donata, Cavalieri Stefano, Alfieri Salvatore, Resteghini Carlo, Bergamini Cristiana, Orlandi Ester, Platini Francesca, Locati Laura, Giacomelli Luca, Licitra Lisa, Bossi Paolo
机构信息
Head and Neck Cancer Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori Milan, Italy.
Radiotherapy 1-2 Units, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
出版信息
Drugs Context. 2019 Dec 19;8:212611. doi: 10.7573/dic.212611. eCollection 2019.
BACKGROUND
Unresectable or metastatic cutaneous squamous cell cancers (cSCCs) are rare but potentially life-threatening diseases. In this setting, systemic therapy has a palliative intent with limited benefit, but there is no established consensus regarding the proper management of this tumour. This retrospective study aimed to review outcomes in patients with non-curable cSCC treated with platinum-based chemotherapy and cetuximab.
METHODS
We considered 12 consecutive patients treated between June 2010 and March 2016. All patients had received previous treatment for the local disease.
RESULTS
The overall response rate was 50%, and the disease control rate was 67%. Median progression-free survival and overall survival were 6.6 (95% confidence interval [CI]: 1.9-8.4) and 14.6 (95% CI: 9.4-20.1) months, respectively. The median duration of response was 4.8 months (95% CI: 1.2-5.9). The most frequent toxicities were skin reactions (58%; grade 3: 25%) and anaemia (10%). No grade 4 toxicities were observed.
CONCLUSIONS
Cetuximab and platinum-based chemotherapy were shown to be feasible and active in cSCC, with an acceptable toxicity profile, even if with a limited duration of response.
背景
不可切除或转移性皮肤鳞状细胞癌（cSCC）虽罕见但可能危及生命。在此情况下，全身治疗具有姑息目的且获益有限，但对于该肿瘤的恰当管理尚无既定共识。这项回顾性研究旨在评估接受铂类化疗联合西妥昔单抗治疗的不可治愈性cSCC患者的治疗结果。
方法
我们纳入了2010年6月至2016年3月期间连续接受治疗的12例患者。所有患者此前均已接受过局部疾病的治疗。
结果
总缓解率为50%，疾病控制率为67%。无进展生存期和总生存期的中位数分别为6.6（95%置信区间[CI]：1.9 - 8.4）个月和14.6（95%CI：9.4 - 20.1）个月。缓解持续时间的中位数为4.8个月（95%CI：1.2 - 5.9）。最常见的毒性反应为皮肤反应（58%；3级：25%）和贫血（10%）。未观察到4级毒性反应。
结论
西妥昔单抗和铂类化疗在cSCC中显示出可行且有效，毒性特征可接受，尽管缓解持续时间有限。
Zotero 插件